Study Graphic

The Pfizer New Haven Clinical Research Unit is conducting a study of a new investigational drug being studied to treat people with moderate to severe atopic dermatitis (AD). AD is a form of eczema (itchy, inflamed skin rash). The dose of the study drug to be used to treat people has not yet been determined. Study drug will be given as tablets, which you will swallow. Portia® will also be given in this study. Portia® is a marketed type of oral (by mouth) birth control. It is a combination of the hormones estrogen and progestogen. In this study you will receive two single oral doses.  In this study you will receive two single oral doses.

You may be eligible if:

  • You are a healthy female, able or unable to have children, between the ages of 18 and 55
  • You are able to meet all eligibility criteria
  • You are able to comply with all study visits

Study Number: B7451016

Be compensated for your time:

  • Group 1: up to $4775.00 for completion of the study
  • Group 2: up to $4925.00 for completion of the study

This study involves:

You will be in this study up to about 43 or 52 days, depending on your subject group. This does not include the time between screening and dosing, which can be up to 28 days.

This study involves:

  • 2 dosing periods (during one continuous admission or two separate admissions, depending on your subject group)
  • 15 overnight stays
  • 1 follow up visit to the clinic (7 to 14 days after the last dose)
  • 1 follow-up phone call (28 to 35 days after the last dose)
  • There will be at least 10 days between dosing periods for subjects who will have two separate admissions

Please review the Informed Consent Document: B7451016 ICD v13Sep2018

Please review more study information: B7451016 final Guidelines-Restriction-Dates v05Sep2018